A pharmacokinetic profile of desloratadine in healthy adults, including elderly
- PMID: 12169042
- DOI: 10.2165/00003088-200241001-00003
A pharmacokinetic profile of desloratadine in healthy adults, including elderly
Abstract
Objective: To characterise the pharmacokinetic profile of desloratadine and its main metabolite, 3-hydroxy (3-OH) desloratadine, in a patient population representative of the population studied in the desloratadine clinical efficacy and safety studies, including the elderly.
Design: A multicentre, multidose, open-label pharmacokinetic trial.
Participants: 113 healthy adult volunteers (57 men, 56 women; 95 White, 18 Black) were enrolled, and 112 completed the study.
Interventions: A 5mg oral dose of desloratadine once daily for 10 days.
Main outcome measures: C(max), t(max), t((1/2)) and AUC(24h).
Results: Steady-state plasma concentrations were attained by day 7. Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration. The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 micro g/L x h for desloratadine and 32.3 micro g/L x h for 3-OH desloratadine. The mean half-lives (t((1/2))) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively. There were no clinically relevant differences in the calculated pharmacokinetic parameters of desloratadine when participants were stratified into 3 age groups (19 to 45, 46 to 64 and 65 to 70 years). Treatment-emergent adverse events occurred in 31 of the 113 participants (3 of the 17 aged >or=65 years reported adverse events). All adverse events were mild to moderate in severity, and none resulted in discontinuation of treatment. There were no consistent clinically relevant changes in blood pressure, pulse, oral body temperature or electrocardiogram evaluations and no reports of syncope or sedation.
Conclusion: Daily administration of desloratadine 5mg is well tolerated. The 27-hour half-life of desloratadine permits once daily administration. No dosage adjustment of desloratadine is required in the elderly.
Similar articles
-
Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.Clin Pharmacokinet. 2002;41 Suppl 1:21-8. doi: 10.2165/00003088-200241001-00004. Clin Pharmacokinet. 2002. PMID: 12169043 Clinical Trial.
-
Desloratadine demonstrates dose proportionality in healthy adults after single doses.Clin Pharmacokinet. 2002;41 Suppl 1:1-6. doi: 10.2165/00003088-200241001-00001. Clin Pharmacokinet. 2002. PMID: 12169040 Clinical Trial.
-
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.Clin Pharmacokinet. 2002;41 Suppl 1:37-44. doi: 10.2165/00003088-200241001-00006. Clin Pharmacokinet. 2002. PMID: 12169045 Clinical Trial.
-
Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. doi: 10.1111/j.1472-8206.2004.00254.x. Fundam Clin Pharmacol. 2004. PMID: 15312146 Review.
-
The pharmacologic profile of desloratadine: a review.Allergy. 2001;56 Suppl 65:7-13. doi: 10.1034/j.1398-9995.2001.00101.x. Allergy. 2001. PMID: 11243504 Review.
Cited by
-
Chronic Urticaria in Older Adults: Treatment Considerations.Drugs Aging. 2023 Mar;40(3):165-177. doi: 10.1007/s40266-023-01010-y. Epub 2023 Feb 18. Drugs Aging. 2023. PMID: 36808569 Review.
-
Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).Turk Arch Otorhinolaryngol. 2021 May;59(Suppl 1):1-157. doi: 10.4274/tao.2021.suppl.1. Turk Arch Otorhinolaryngol. 2021. PMID: 34212158 Free PMC article.
-
Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):337-48. doi: 10.1007/s00210-008-0369-5. Epub 2008 Nov 11. Naunyn Schmiedebergs Arch Pharmacol. 2009. PMID: 19002438
-
Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.Clin Pharmacol Ther. 2015 Sep;98(3):321-7. doi: 10.1002/cpt.150. Clin Pharmacol Ther. 2015. PMID: 25975815 Free PMC article.
-
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources